Glycomet-GP 3/850 Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 3 mg and Metformin 850 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle cells. The combination of these agents provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled by diet, exercise, and monotherapy. Glycomet-GP 3/850 Tablet PR is designed for prolonged release, allowing for once-daily dosing, which may improve patient compliance. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily attributed to Metformin, while hypoglycemia may occur due to Glimepiride. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to hypoglycemia. This medication should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.